the rule be amended to include joint ventures whose primary purpose is the exploration and development of oil and coal and other non-utility ventures, so that a registered holding company with an electric utility system may benefit from the rule by participating in joint projects to secure such fuels for its generating facilities.

The acquisition by electric utilities of captive or affiliated sources of fuel supply has led to considerable controversy about the cost, economies, and other presumed advantages of the acquisitions. Such acquisitions are of special concern to utility commissions, which, among other things, have been particularly troubled about how the price the electric utility pays to its fuel affiliate, not an arm's-length transaction, should be considered under fuel adjustment clauses. In these circumstances, the Commission does not believe it appropriate to adopt an exemptive rule to encourage the development of these sources of fuel supply and therefore is not incorporating such revisions into Rule 16. Moreover, the proposed expansion of the rule would require republication for comment and would necessarily involve an indefinite delay in promulgating Rule 16, which, within present bounds, is ready for adoption now.

Statutory Basis and Text of the Rule

The Securities and Exchange Commission hereby amends Title 17, Chapter II of the Code of Federal Regulations, pursuant to its authority under the Public Utility Holding Company Act of 1935 [15 U.S.C. 79a *et seq.*] and particularly Sections 3(d) and 20 (a) thereof [15 U.S.C. 79c(d) and 79t(a)] by adding § 250.16 to read as set forth below. This action is effective immediately pursuant to the Administrative Procedure Act [5 U.S.C. 553(d)(1)].

PART 250—GENERAL RULES AND REGULATIONS, PUBLIC UTILITY HOLDING COMPANY ACT OF 1935

§ 250.16 Exemption of non-utility subsidiaries and affiliates.

(a) Any company, and each affiliate thereof, shall be exempt from all obligations, duties or liabilities imposed upon it by the Act, as a subsidiary company or as an affiliate of a registered holding company or of a subsidiary company thereof, as such terms are respectively defined in sections 2(a)(8)(A) and 2(a)(11) of the Act, if—

(1) Such company is not a public utility company as defined in section 2(a)(5) of the Act;

(2) Such company is or has been organized to engage primarily in the exploration, development, production, manufacture, storage, transportation or supply of natural or synthetic gas;

(3) No more than 50% of its voting securities or other voting interests are owned, directly or indirectly, by one or more registered holding companies; and

(4) The acquisition by the registered holding company or subsidiary thereof of its interest in such company has been approved by the Commission pursuant to sections 9(a)(1) and 10 of the Act and applicable rules thereunder upon a timely application to the Commission.

(b) The exemption provided by this rule shall continue in effect during the pendency of such application. If an acquisition is made subject to Commission approval, the exemption provided by this rule is not terminated if the Commission does not grant its approval. In that event any such acquisition shall be disposed of in accordance with the order of the Commission.

(c) If a registered holding company directly or indirectly acquires any voting securities of such company, or any other voting interest, pursuant to this rule, the holding company shall include as an exhibit to its annual report on Form U5S a copy of the annual report of such company. It may incorporate by reference the annual report such company is required to file pursuant to other statutes administered by the Commission.

(d) This rule does not affect the authority of any agency having jurisdiction over rates with respect to a company exempt under this rule, including authority over affiliate transactions by or with such company pursuant to the laws administered by that agency.

By the Commission.

George A. Fitzsimmons,

Secretary.

November 19, 1980.

[FR Doc. 80-37105 Filed 11-26-80; 8:45 am]

BILLING CODE 8010-01-M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

18 CFR Part 375

[Docket No. RM81-5; Order No. 112]

Rule Revision Subdelegation Authority

November 21, 1980.

AGENCY: Federal Energy Regulatory Commission, DOE.

ACTION: Final rule.

SUMMARY: The Federal Energy Regulatory Commission revises its rules of practice and procedure to permit an official to whom the Commission has delegated certain functions under Part 375 to subdelegate the authority to carry out those functions to the deputy of such official, to the head of a division, or a comparable official.

EFFECTIVE DATE: November 21, 1980.

FOR FURTHER INFORMATION CONTACT: Christine R. Benagh, Staff Attorney, Regulatory Development, Office of the General Counsel, Federal Energy Regulatory Commission, 825 North Capitol Street NE., Washington, D.C. 20426, (202) 357-8062.

The Federal Energy Regulatory Commission (Commission) hereby revises its rules of practice and procedure relating to delegations, to permit subdelegations of authority previously delegated to certain officials by the Commission.

I. Background and Discussion

The Commission, in the past, has delegated to specific Commission officials certain of its ministerial regulatory functions, which appear in Part 375, Subpart C, of the Commission's rules and regulations. The officials who carry out these delegated functions include the Secretary of the Commission, the Chief Accountant, the Director of the Office of Pipeline and Producer Regulation, the Director of the Office of Electric Power Regulation, and the Solicitor. Before the revision promulgated herein, these officials could subdelegate these functions only in the event of their absence. The Commission believes that permitting subdelegation only when such officials are absent may hinder efficient administration of its duties and responsibilities.

Therefore, the rules of the Commission are being revised, in the interest of efficient administration, to delete the limitations which permit a subdelegation only when the delegatee of the Commission is absent. The subpart on delegations is also being amended to clarify to which officials a subdelegation may be made: the deputy of the Commission's delegatee, the head of a division, or a comparable official.

In consideration of the foregoing, the Commission is revising its rules to permit subdelegations, under Part 375, Subpart C of its rules of practice and procedure, to certain classes of Commission officials even when the Commission's delegatee is not absent.

II. Public Procedures and Effective Date

Since this rule concerns a matter of agency practice and procedure, notice and public comment thereon is unnecessary pursuant to 5 U.S.C. 553(b). The Commission believes that the delegated functions, which appear in Part 375, Subpart C, of the Commission's regulations, will be administered more easily and more efficiently if this rule is made effective as soon as possible. Therefore, the Commission finds that good cause exists pursuant to 5 U.S.C. 553(d)(3) to make this rule effective immediately.

(Department of Energy Organization Act, (42 U.S.C. 7107 *et seq.;* Federal Power Act, (16 U.S.C.), 791–828c), as amended; Natural Gas Act, (15 U.S.C. 717–717w), as amended; Natural Gas Policy Act of 1978, (15 U.S.C. 3301 *et seq.);* Public Utilities Regulatory Policies Act of 1978, (16 U.S.C. 2601 *et seq.);* Exec. Order No. 12009, 3 CFR 142 (1978))

In consideration of the foregoing, the Commission amends Subpart C, Part 375, Subchapter W, Chapter I, Title 18 of the Code of Federal Regulations as set forth below, effective November 21, 1980.

By the Commission.

Kenneth F. Plumb,

Secretary.

1. Part 375 is amended in the table of contents and in the text of the regulations of § 375.301 to read as follows:

§ 375.301 Purpose and subdelegations.

(a) The purpose of this subpart is to set forth the authorities that the Commission has delegated to staff officials. Any action by a staff official under the authority of this subpart may be appealed to the Commission in accordance with § 1.7(d) of this chapter.

(b) Where the Commission, in delegating functions to specified Commission officials, permits an official to further delegate those functions to a designee of such official, "designee" shall mean the deputy of such offical, the head of a division, or a comparable official as designated by the official to whom the direct delegation is made.

§ 375.302 [Amended]

3. Section 375.302 is amended in the first sentence to delete "in the Secretary's absence,".

§ 375.303 [Amended]

4. Section 375.303 is amended in the first sentence to delete "in the Chief Accountant's absence,".

§ 375.305 [Amended]

5. Section 375.305 is amended in the first sentence to delete "in the Solicitor's absence,".

§§ 375.307—375.310 [Amended]

6. Sections 375.307, 375.308, 375.309, and 375.310, are each amended in the first sentence to delete "in the Director's absence,".

[FR Doc. 80-37040 Filed 11-26-80; 8:45 am]

BILLING CODE 6450-85-M

DEPARTMENT OF COMMERCE

International Trade Administration

19 CFR Part 355

Certain Fish From Canada; Revocation of Countervailing Duty Orders

AGENCY: International Trade Administration, Commerce.

ACTION: Revocation of Countervailing Duty Orders.

SUMMARY: This notice is to advise the public that, as a result of a negative injury determination by the International Trade Commission, the Department of Commerce is revoking the countervailing duty orders on certain fish from Canada. The table in Part 355, Annex III of the Commerce Regulations is amended to reflect these revocations.

EFFECTIVE DATE: January 1, 1980.

FOR FURTHER INFORMATION CONTACT: Lorenza Olivas, Office of Compliance, International Trade Administration, U.S. Department of Commerce, Room 1126, Washington, D.C. 20230 (202–377–5222).

SUPPLEMENTARY INFORMATION: Three separate notices of "Final Countervailing Duty Determination" were published in the **Federal Register:** T.D. 77–107, April 13, 1977 (42 FR 19326), T.D. 78–181, June 16, 1978 (43 FR 25996) and T.D. 79–07, January 5, 1979 (44 FR 1372). The notices stated that the Treasury Department had determined that exports of certain fish from Canada were provided bounties or grants, within the meaning of section 303 of the Tariff Act of 1930 (19 U.S.C. 1303) ("the Act"). Concurrently with those determinations, the following notices were published waiving the imposition of countervailing duties under the authority of section 303(d) of the Act: T.D. 77–108 (42 FR 19237), T.D. 78–182 (32 FR 25995) and T.D. 79–08 (44 FR 1728).

On January 1, 1980, Title I of the Trade Agreements Act of 1979 (19 U.S.C. 1671 et seq.) ("the TAA") went into effect. On January 2, 1980, the authority for administering the countervailing duty laws was transferred from the Department of the Treasury to the Department of Commerce ("the Department"). Since Canada was a "country under the Agreement" (as defined in section 701(b) of the Act) as of January 1, 1980, the Department referred these cases to the International Trade Commission ("the ITC") for a material injury determination in accordance with section 104(a)(1)(A) of the TAA. Section 105 of the TAA continued the waiver pending the ITC determination. Liquidation continued throughout the period. The ITC published a negative material injury decision in the **Federal Register** of May 22, 1980 (45 FR 34456).

As a result, the Department hereby revokes Treasury Decisions 77–107, 77–108, 78–181, 78–182, 79–07 and 79–08 with respect to all entries of certain fish from Canada. The Department will instruct customs officers to continue liquidation of all such entries without regard to countervailing duties.

PART 355—COUNTERVAILING DUTIES

The table in Part 355, Annex III, Commerce Regulations (19 CFR Part 355, Annex III, 45 FR 4949), is amended under the country heading "Canada" by deleting from the column headed "Commodity", the words "Groundfish" (in two places) and "Fish"; from the column headed "Treasury Decision", the numbers "77–107", "78–181" and "79–07"; and from the column headed "Action", the words "Bounty declared-rate" (in three places).

(Sec. 104(a)(3)(B) of the TAA (93 Stat. 191, 19 U.S.C. 1671 note))

John D. Greenwald,

Deputy Assistant Secretary for Import Administration.

November 24, 1980.

[FR Doc. 80-37121 Filed 11-26-80; 8:45 am]

BILLING CODE 3510-25-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 14

Advisory Committees; Establishment

AGENCY: Food and Drug Administration.

ACTION: Final rule.

SUMMARY: Under the Federal Advisory Committee Act of October 6, 1972, and the public advisory committee procedures (21 CFR Part 14), the Food and Drug Administration (FDA) announces the establishment of the Anti-Infective Drugs Advisory Committee, the Dermatologic Drugs Advisory Committee, and the Ophthalmic Drugs Advisory Committee. This document adds to the agency's list of standing advisory committees. In notices published elsewhere in this issue of the **Federal Register,** FDA asks for

nominations for membership on these committees. This document also deletes the Anti-Infective and Topical Drugs Advisory Committee from the list of standing committees because its charter expired on April 10, 1980.

DATES: Effective November 28,1980; authority for the committees being established will end on October 7, 1982, unless the Secretary formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Richard L. Schmidt, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2765.

SUPPLEMENTARY INFORMATION: Under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92–463) and § 14.40(b) (21 CFR 14.40(b)), FDA announces the establishment of the Anti-Infective Drugs Advisory Committee, the Dermatologic Drugs Advisory Committee, and the Ophthalmic Drugs Advisory Committee.

The Anti-Infective Drugs Advisory Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational prescription drug products for use in the treatment of infectious diseases and makes appropriate recommendations to the Commissioner of Food and Drugs. The Committee will have 11 members.

The Dermatologic Drugs Advisory Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational prescription drug products for use in the treatment of dermatologic diseases and makes appropriate recommendations to the Commissioner of Food and Drugs. The Committee will have 11 members.

The Ophthalmic Drugs Advisory Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational prescription drug products for use in the treatment of ocular diseases and makes appropriate recommendations to the Commissioner of Food and Drugs. The Committee will have 11 members.

Therefore, under the Federal Food, Drug, and Cosmetic Act (sec. 701(a), 52 Stat. 1055 (21 U.S.C. 371(a))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.1), Part 14 is amended in § 14.100 by revising paragraph (c), to read as follows:

§ 14.100 List of standing advisory committees.

* * * * *

(c) *Bureau of Drugs*—(1) *Anesthetic and Life Support Drugs Advisory Committee.* (i) Date established: May 1, 1978.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in the field of anesthesiology and surgery.

(2) *Anti-Infective Drugs Advisory Committee.* (i) Date established: October 7, 1980.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in infectious diseases.

(3) *Arthritis Advisory Committee.* (i) Date established: April 5, 1974.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in arthritic conditions.

(4) *Cardiovascular and Renal Drugs Advisory Committee.* (i) Date established: August 27, 1970.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in cardiovascular and renal disorders.

(5) *Dermatologic Drugs Advisory Committee.* (i) Date established: October 7, 1980.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in the treatment of dermatologic diseases.

(6) *Drug Abuse Advisory Committee.* (i) Date established: May 31, 1978.

(ii) Function: Advises on the scientific and medical evaluation of information gathered by the Department of Health and Human Services and the Department of Justice on the safety, efficacy, and abuse potential of drugs and recommends actions to be taken on the marketing, investigation, and control of such drugs.

(7) *Endocrinologic and Metabolic Drugs Advisory Committee.* (i) Date established: August 27, 1970.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in endocrine and metabolic disorders.

(8) *Fertility and Maternal Health Drugs Advisory Committee.* (i) Date established: March 23, 1978.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in the practice of obstetrics and gynecology.

(9) *Gastrointestinal Drugs Advisory Committee.* (i) Date established: March 3, 1978.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in gastrointestinal diseases.

(10) *Oncologic Drugs Advisory Committee.* (i) Date established: September 21, 1978.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in the treatment of cancer.

(11) *Ophthalmic Drugs Advisory Committee.* (i) Date established: October 7, 1980.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in the treatment of ocular diseases.

(12) *Peripheral and Central Nervous System Drugs Advisory Committee.* (i) Date established: June 4, 1974.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in neurologic disease.

(13) *Psychopharmacologic Drugs Advisory Committee.* (i) Date established: June 4, 1974.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in the practice of psychiatry and related fields.

(14) *Pulmonary-Allergy Drugs Advisory Committee.* (i) Date established: February 17, 1972.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in the treatment of pulmonary disease and diseases with allergic and/or immunologic mechanisms.

(15) *Radiopharmaceutical Drugs Advisory Committee.* (i) Date established: August 30, 1967.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of marketed and investigational prescription drugs for use in the practice of nuclear medicine.

(16) *Advisory review panels for over-the-counter (OTC) drugs.* (i) Dates established—(*a*) *Antimicrobial Panel.* Established March 16, 1972;

(*b*) [Reserved]

(c) *Miscellaneous Internal Drug Products Panel.* Established July 16, 1973; and

(d) *Miscellaneous External Drug Products Panel.* Established July 16, 1973.

(ii) Function: Reviews and evaluates available data on the safety and effectiveness of nonprescription drug products.

* * * * *

Effective date. Since this is a technical conforming amendment to Part 14, the Commissioner finds that there is good cause for the rule to be published without notice and comment and to be effective immediately upon publication in the **Federal Register**, November 28, 1980.

(Sec. 701(a), 52 Stat. 1055 (21 U.S.C. 371(a)))

Dated: November 20, 1980.

William F. Randolph,

Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 80-37035 Filed 11-26-80; 8:45 am]

BILLING CODE 4110-03-M

---

21 CFR Parts 510, 558

New Animal Drugs and New Animal Drugs for Use in Animal Feeds; Tylosin

AGENCY: Food and Drug Administration.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the regulations to reflect approval of a new animal drug application (NADA) filed for Micro Blenders, Inc., providing for safe and effective use of a 10 gram-per-pound tylosin premix for making complete swine feeds, and to add this firm to the list of approved NADA sponsors.

EFFECTIVE DATE: November 28, 1980.

FOR FURTHER INFORMATION CONTACT: Jack C. Taylor, Bureau of Veterinary Medicine (HFV-136), Food and Drug Administration, 5600 Fishers Lane, Rockville MD 20857, 301-443-5247.

SUPPLEMENTARY INFORMATION: Micro Blenders, Inc., is sponsor of NADA 123-065 submitted on its behalf by Elanco Products Co. The NADA provides for use of a premix containing 10 grams of tylosin (as tylosin phosphate) per pound for making complete swine feeds used to increase rate of weight gain and improve feed efficiency.

Approval of this NADA relies upon safety and effectiveness data contained in Elanco Product Co.'s approved NADA 12-491. Use of the data in NADA 12-491 to support this NADA has been authorized by Elanco. This approval does not change the approved use of the drug. Consequently, approval of this NADA poses no increased human risk from exposure to residues of the animal drug, nor does it change the conditions of the drug's safe use in the target animal species. Accordingly, under the Bureau of Veterinary Medicine supplemental approval policy (42 FR 64367; December 23, 1977) approval of this NADA has been treated as would approval of a category II supplement and did not require reevaluation of safety and effectiveness data in NADA 12-491.

Micro Blenders, Inc., has not previously been included in the regulations in the list of approved sponsors. The regulations are amended to reflect this approval and to include this firm in the list of sponsors.

The agency has determined pursuant to 21 CFR 25.24(d)(1) (proposed December 11, 1979; 44 FR 71742) that this action is of a type that does not individually or cumulatively have a significant impact on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

In accordance with the freedom of information provisions of Part 20 (21 CFR Part 20) and § 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of the safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (formerly the Hearing Clerk's office) (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, from 9 a.m. to 4 p.m., Monday through Friday.

Therefore, under the Federal Food, Drug, and Cosmetic Act (sec. 512(i), 82 Stat. 347 (21 U.S.C. 360b(i))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.1) and redelegated to the Bureau of Veterinary Medicine (21 CFR 5.83), Parts 510 and 558 are amended as follows:

1. In Part 510, § 510.600 is amended by adding a new sponsor alphabetically to paragraph (c)(1) and numerically to paragraph (c)(2), to read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

* * * * *

(c) * * *

(1) * * *

Firm name and address	Drug labeler code
* * * * *	
Micro Blenders, Inc., Highway 210 E. at 291, P.O. Box 357, Liberty, MO 64068	050782
* * * * *	

(2) * * *

Drug labeler code	Firm name and address
* * * * *	
050782	Micro Blenders, Inc., Highway 210 E. at 291, P.O. Box 357, Liberty, MO 64068.
* * * * *	

2. In Part 558, § 558.625 is amended by adding new paragraph (b)(74), to read as follows:

§ 558.625 Tylosin.

* * * * *

(b) * * *

(74) To 050782: 10 grams per pound: paragraph (f)(1)(vi)(*a*) of this section.

* * * * *

Effective date. This regulation is effective November 28, 1980.

(Sec. 512(i), 82 Stat. 347, (21 U.S.C. 360b(i)))

Dated: November 19, 1980.

Gerald B. Guest,

Acting Director, Bureau of Veterinary Medicine.

[FR Doc. 80-36871 Filed 11-26-80; 8:45 am]

BILLING CODE 4110-03-M

---

21 CFR Parts 510, 558

New Animal Drugs and New Animal Drugs for Use in Animal Feeds; Tylosin

AGENCY: Food and Drug Administration.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the regulations to reflect approval of a new animal drug application (NADA) filed for Webel Feeds, Inc., providing for use of 0.8-, 1-, 2-, and 10-gram-per-pound tylosin premixes for making complete cattle and swine feeds, and to add this firm to the list of approved NADA sponsors.

EFFECTIVE DATE: November 29, 1980.

FOR FURTHER INFORMATION CONTACT: Jack C. Taylor, Bureau of Veterinary Medicine (HFV-136), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5247.

SUPPLEMENTARY INFORMATION: Webel Feeds, Inc., R.R. 3, Pittsfield, IL 62363, is the sponsor of an NADA (116-196)